An update on the use of rifapentine for tuberculosis therapy

Expert Opinion on Drug Delivery

Volumn 11, Issue 3, 2014, Pages 421-431

  Chan, John Gar Yan ^a   Bai, Xiaoxue ^b   Traini, Daniela ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Aerosol; Inhalation; Rifamycin; Rifapentine; Tuberculosis

Indexed keywords

RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ANALOGS AND DERIVATIVES; ANIMAL; DRUG ADMINISTRATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; TUBERCULOSIS, PULMONARY;

ADMINISTRATION, INHALATION; ANIMALS; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 84894443760     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.877886     Document Type: Review

References (99)

1. Arioli V, Berti M, Carniti G, et al. Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative. J Antibiot (Tokyo) 1981;34(8):1026-32
2. Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the treatment of pulmonary tuberculosis. Clin infect Dis 2006;43(11):1468-75
3. Wade MM, Zhang Y. Mechanisms of drug resistance in Mycobacterium tuberculosis. Front Biosci 2004;9:975-94
4. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1979;76(6 Suppl):771-81
5. Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981;123(4 Pt 1):367-71
6. van Ingen J, Aarnoutse RE, Donald PR, et al. Why do we use 600 mg of rifampicin in tuberculosis treatment?. Clin infect Dis 2011;52(9):e194-9
7. Mitchison DA. Pharmacokinetic/ pharmacodynamic parameters and the choice of high-dosage rifamycins. Int J Tuberc Lung Dis 2012;16(9):1186-9
8. Mor N, Simon B, Mezo N, et al. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chemother 1995;39(9):2073-7
9. Rastogi N, Goh KS, Berchel M, et al. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. J Antimicrob Chemother 2000;46(4):565-70
10. Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4(12):e344
11. Bemer-Melchior P, Bryskier A, Drugeon HB. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother 2000;46(4):571-6
12. Ji B, Truffot-Pernot C, Lacroix C, et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993;148(6 Pt 1):1541-6
13. Heifets LB, Lindholm-Levy PJ, Flory MA. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis 1990;141(3):626-30
14. Sirgel FA, Fourie PB, Donald PR, et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005;172(1):128-35
15. Dickinson JM, Mitchison DA. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 1987;68(2):113-18
16. Moghazeh SL, Pan X, Arain T, et al. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 1996;40(11):2655-7
17. Bodmer T, Zurcher G, Imboden P, et al. Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicinresistant Mycobacterium tuberculosis. J Antimicrob Chemother 1995;35(2):345-8
18. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000;4(9):796-806
19. Holland DP, Sanders GD, Hamilton CD, et al. Costs and costeffectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009;179(11):1055-60
20. Holland DP, Sanders GD, Hamilton CD, et al. Potential economic viability of two proposed rifapentinebased regimens for treatment of latent tuberculosis infection. PLoS One 2011;6(7):e22276
21. de Castilla DL, Rakita RM, Spitters CE, et al. Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates. Transplantation 2013. [Epub ahead of print]
22. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365(23):2155-66
23. Bemis K, Lobato M, Sosa L. Use of 12-Dose Isoniazid and Rifapentine for the Treatment of Latent Tuberculosis in Connecticut. 2013 CSTE Annual Conference; California; 2013
24. Sharma SK, Sharma A, Kadhiravan T, et al. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIVnegative people at risk of active TB. Cochrane Database Syst Rev 2013;7:CD007545
25. Dooley KE, Bliven-Sizemore EE, Weiner M, et al. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther 2012;91(5):881-8
26. Gao XF, Li J, Yang ZW, et al. Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: A systematic review. Int J Tuberc Lung Dis 2009;13(7):810-19
27. Centers for Disease Control and Prevention (CDC). Treatment of tuberculosis. Atlanta, USA; 2003
28. Rosenthal IM, Tasneen R, Peloquin CA, et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 2012;56(8):4331-40
29. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180(3):273-80
30. Rosenthal IM, Zhang M, Grosset JH, et al. Rifapentine-containing regimens cure murine tuberculosis in weeks rather than months. Am J Respir Crit Care Med 2008;177:A789
31. Zhang T, Zhang M, Rosenthal IM, et al. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 2009;180(11):1151-7
32. Zhang T, Li SY, Williams KN, et al. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 2011;184(6):732-7
33. Harper J, Skerry C, Davis SL, et al. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 2012;205(4):595-602
34. Dutta NK, Illei PB, Peloquin CA, et al. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agents Chemother 2012;56(7):3726-31
35. Ahmad Z, Klinkenberg LG, Pinn ML, et al. Biphasic kill curve of isoniazid reveals the presence of drug-Tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis 2009;200(7):1136-43
36. Ahmad Z, Nuermberger EL, Tasneen R, et al. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother 2010;65(4):729-34
37. Aristoff PA, Garcia GA, Kirchhoff PD, et al. Rifamycins-obstacles and opportunities. Tuberculosis 2010;90(2):94-118
38. Coates AR, Hu Y, Jindani A, et al. Contradictory results with high-dosage rifamycin in mice and humans. Antimicrob Agents Chemother 2013;57(2):1103
39. Nuermberger EL, Rosenthal IM, Tasneen R, et al. Reply to Contradictory results with high-dosage rifamycin in mice and humans. Antimicrob Agents Chemother 2013;57(2):1104-5
40. Emary WB, Toren PC, Mathews B, et al. Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys. Drug Metab Dispos 1998;26(8):725-31
41. Dooley K, Flexner C, Hackman J, et al. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother 2008;52(11):4037-42
42. Dutta NK, Alsultan A, Peloquin CA, et al. Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs. Antimicrob Agents Chemother 2013;57(3):1535-7
43. Hosagrahara V, Reddy J, Ganguly S, et al. Effect of repeated dosing on rifampin exposure in BALB/c mice. Eur J Pharm Sci 2013;49(1):33-8
44. Dorman SE, Goldberg S, Stout JE, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: Study 29 of the tuberculosis trials consortium. J Infect Dis 2012;206(7):1030-40
45. Temple ME, Nahata MC. Rifapentine: Its role in the treatment of tuberculosis. Ann Pharmacother 1999;33(11):1203-10
46. Zvada SP, Van Der Walt JS, Smith PJ, et al. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother 2010;54(8):3390-4
47. Peloquin CA, Namdar R, Singleton MD, et al. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999;115(1):12-18
48. Pandey R, Khuller GK. Antitubercular inhaled therapy: Opportunities, progress and challenges. J Antimicrob Chemother 2005;55(4):430-5
49. Mathias NR, Hussain MA. Non-invasive systemic drug delivery: Developability considerations for alternate routes of administration. J Pharm Sci 2010;99(1):1-20
50. Misra A, Hickey AJ, Rossi C, et al. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 2011;91(1):71-81
51. Garcia-Contreras L, Fiegel J, Telko MJ, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother 2007;51(8):2830-6
52. Coowanitwong I, Arya V, Kulvanich P, et al. Slow release formulations of inhaled rifampin. AAPS J 2008;10(2):342-8
53. Dharmadhikari AS, Kabadi M, Gerety B, et al. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: A new approach to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother 2013;57(6):2613-19
54. Weiner M, Bock N, Peloquin CA, et al. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med 2004;169(11):1191-7
55. Mizoe T, Ozeki T, Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicincontaining mannitol microparticles. AAPS PharmSciTech 2008;9(3):755-61
56. Muttil P, Kaur J, Kumar K, et al. Inhalable microparticles containing large payload of anti-Tuberculosis drugs. Eur J Pharm Sci 2007;32(2):140-50
57. O'Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization. Pharm Res 2000;17(8):955-61
58. Sharma R, Saxena D, Dwivedi AK, et al. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 2001;18(10):1405-10
59. Sharma R, Yadav AB, Muttil P, et al. Inhalable microparticles modify cytokine secretion by lung macrophages of infected mice. Tuberculosis 2011;91(1):107-10
60. Sung JC, Garcia-Contreras L, Verberkmoes JL, et al. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob Agents Chemother 2009;53(4):1338-43
61. Tsapis N, Bennett D, O'Driscoll K, et al. Direct lung delivery of paraaminosalicylic acid by aerosol particles. Tuberculosis 2003;83(6):379-85
62. Verma RK, Kaur J, Kumar K, et al. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother 2008;52(9):3195-201
63. Verma RK, Singh AK, Mohan M, et al. Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug-delivery systems. Ther Deliv 2011;2(6):753-68
64. Yadav AB, Sharma R, Muttil P, et al. Inhalable microparticles containing isoniazid and rifabutin target macrophages and 'stimulate the phagocyte' to achieve high efficacy. Indian J Exp Biol 2009;47(6):469-74
65. Suarez S, O'Hara P, Kazantseva M, et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model. Pharm Res 2001;18(9):1315-19
66. Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: A meta-Analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin infect Dis 2009;49(12):1883-9
67. Garcia-Contreras L, Sung JC, Muttil P, et al. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother 2010;54(4):1436-42
68. Kumar Verma R, Mukker JK, Singh RS, et al. Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. Mol Pharm 2012;9(4):1011-16
69. Hickey AJ, Misra A, Fourie PB. Dry powder antibiotic aerosol product development: Inhaled therapy for tuberculosis. J Pharm Sci 2013;102(11):3900-7
70. Son YJ, McConville JT. A new respirable form of rifampicin. Eur J Pharm Biopharm 2011;78(3):366-76
71. Son YJ, McConville JT. Preparation of sustained release rifampicin microparticles for inhalation. J Pharm Pharmacol 2012;64(9):1291-302
72. Zhang M, Li SY, Rosenthal IM, et al. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med 2011;183(9):1254-61
73. Shu JY, Quan XY, Shu Y, et al. Preparation, characterization, and pulmonary delivery of rifapentine liposomes modified by lauric diethanolamide. Yao Xue Xue Bao 2006;41(8):761-4
74. Yang Z. Study on rifapentine-sodium alginate microspheres for lung targeting drug delivery [PhD]. Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China; 2011
75. Pandey R, Sharma S, Khuller GK. Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int J Antimicrob Agents 2004;24(1):93-4
76. Ahmad Z, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005;26(4):298-303
77. Vyas SP, Kannan ME, Jain S, et al. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 2004;269(1):37-49
78. Gursoy A, Kut E, Ozkirimli S. Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of liposomes by derivative spectroscopy. Int J Pharm 2004;271(1-2):115-23
79. Prankerd RJ, Walters JM, Parnes JH. Kinetics for degradation of rifampicin, an azomethine-containing drug which exhibits reversible hydrolysis in acidic solutions. Int J Pharm 1992;78(1):59-67
80. Hirota K, Hasegawa T, Nakajima T, et al. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J Control Release 2010;142(3):339-46
81. Garcia-Contreras L, Sethuraman V, Kazantseva M, et al. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. J Antimicrob Chemother 2006;58(5):980-6
82. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366(23):2151-60
83. Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008;322(5906):1392-5
84. Nikonenko BV, Protopopova M, Samala R, et al. Drug therapy of experimental tuberculosis (TB): Improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007;51(4):1563-5
85. Lanoix JP, Nuermberger E. Sutezolid, oxazolidinone antibacterial treatment of tuberculosis. Drug Fut 2013;38(6):387-94
86. Salomon JJ, Galeron P, Schulte N, et al. Biopharmaceutical in vitro characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis. Ther Deliv 2013;4(8):915-23
87. Hoshino K, Inoue K, Murakami Y, et al. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob Agents Chemother 2008;52(1):65-76
88. Nikonenko BV, Reddy VM, Protopopova M, et al. Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis. Antimicrob Agents Chemother 2009;53(7):3138-9
89. Balasubramanian V, Solapure S, Iyer H, et al. Bactericidal activity and mechanism of action of AZD5847: A novel oxazolidinone for the treatment of tuberculosis. Antimicrob Agents Chemother 2013. [Epub ahead of print]
90. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: A randomised trial. Lancet 2012;380(9846):986-93
91. Chan JG, Chan HK, Prestidge CA, et al. A novel dry powder inhalable formulation incorporating three first-line anti-Tubercular antibiotics. Eur J Pharm Biopharm 2012. [Epub ahead of print]
92. Ober CA, Kalombo L, Swai H, et al. Preparation of rifampicin/lactose microparticle composites by a supercritical antisolvent-drug excipient mixing technique for inhalation delivery. Powder Technol 2013;236:132-8
93. Doan TV, Couet W, Olivier JC. Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery. Int J Pharm 2011;414(1-2):112-17
94. Sung JC, Padilla DJ, Garcia-Contreras L, et al. Formulation and pharmacokinetics of self-Assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 2009;26(8):1847-55
95. Hu C, Feng H, Zhu C. Preparation and characterization of rifampicin-PLGA microspheres/sodium alginate in situ gel combination delivery system. Colloids Surf B Biointerfaces 2012;95:162-9
96. Diab R, Brillault J, Bardy A, et al. Formulation and in vitro characterization of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabilizer: Efficiency for ex vivo alveolar macrophage targeting. Int J Pharm 2012;436(1-2):833-9
97. Bhise SB, More AB, Malayandi R. Formulation and in vitro evaluation of rifampicin loaded porous microspheres. Sci Pharm 2010;78(2):291-302
98. Cassano R, Trombino S, Ferrarelli T, et al. Respirable rifampicin-based microspheres containing isoniazid for tuberculosis treatment. J Biomed Mater Res A 2011. [Epub ahead of print]
99. Nimje N, Agarwal A, Saraogi GK, et al. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target 2009;17(10):777-87